5 Best Low-Priced Stocks To Buy Now

1. Viatris Inc. (NASDAQ:VTRS)

Number of Hedge Fund Holders:  47

Generic and specialty pharmaceuticals company Viatris Inc. (NASDAQ:VTRS) became net-income positive in the fourth quarter of 2022 as it posted a net income (GAAP) of $1 billion for the period, compared to a net loss of $263.8 million posted in the same period last year.

As of the end of the fourth quarter of 2022, 47 hedge funds tracked by Insider Monkey had stakes in Viatris Inc. (NASDAQ:VTRS).

Miller Value Partners made the following comment about Viatris Inc. (NASDAQ:VTRS) in its Q4 2022 investor letter:

“Viatris Inc. (NASDAQ:VTRS) gained after reporting 3Q22 net sales of $4.07B, -10.0% Y/Y (-1% operationally), below consensus of $4.14B, and Adjusted EBITDA of $1.50B (36.8% margin), ahead of consensus of $1.44B. Free cash flow (FCF) for the quarter came in at $765.1MM, which brings trailing twelve-month (TTM) FCF to $2.88B, or a FCF yield of 22.9%. Viatris paid down ~$614MM of debt in the quarter, bringing YTD debt reduction to ~$2.1B, in-line with the company’s previously stated target of reducing debt by ~$6.5B between 2021-2023. Additionally, the company announced the acquisitions of two Ophthalmology (eyecare) companies, Oyster Point Pharma and Famy Life Sciences, for an aggregate purchase price of ~$700-750MM, with management expecting these transactions to add at least $1B in sales and $500MM in Adjusted EBITDA to Viatris by 2028.”

You can also take a peek at 30 Countries with the Highest GDP in 2022 and 11 Best Debt Free Stocks to Buy.